Objective To observe the clinical curative effect of Gubenzhike granule on cough variant asthma (CVA), and explore its mechanism. Methods A total of 140 cases of CVA were randomly divided into two groups, 70 cases for each group. The treatment group took Gubenzhike granule orally, and the control group inhaled Budesonide Powder for Inhalation and Salbutamol Sulphate Aerosol, respectively for 8 weeks, with 8 weeks follow-up after treatment. The same nursing intervention was implemented in two groups. Cough symptom scores of the two groups were observed after treatment and at the end of follow-up, the number of eosnophils (EOS) and content of immunoglobulin E (IgE) in peripheral blood were also observed. Results The treatment group completed 67 cases and the control group completed 66 cases. After treatment, the cough symptom scores, EOS and IgE in two groups were significantly reduced (P<0.01, P<0.05), and the cough symptom score of treatment group decreased more significantly than that of control group (P<0.01). The total effective rate and recurrence rate were 91.04%and 9.84%in treatment group, and 83.33% and 30.91% in control group. The total effective rate of treatment group was better than the control group (P<0.01), and the recurrence rate was lower than the control group (P<0.01). Conclusion Gubenzhike granule showed significant effect and low recurrence rate on CVA. Good anti-inflammatory and antianaphylaxis effects may be one of its mechanisms.